Who are Anti-IL6's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SARILUMAB, Tocilizumab plus methotrexate, Recaticimab and Statin, TCI507, Placebo to tocilizumab, Tocilizumab(400mg).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-il6.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Anti-IL6 — Competitive Intelligence Brief

Anti-IL6 (Anti-IL6) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-inflammatory. Area: Immunology.

phase 1 Anti-inflammatory IL-6 receptor Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Anti-IL6 (Anti-IL6) — Marie Hudson, MD. IL-6 receptor antagonist

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti-IL6 TARGET	Anti-IL6	Marie Hudson, MD	phase 1	Anti-inflammatory	IL-6 receptor
SARILUMAB	SARILUMAB		marketed	Interleukin-6 Receptor Antagonist [EPC]	IL-6 receptors (sIL-6R and mIL-6R)	2017-01-01
Tocilizumab plus methotrexate	Tocilizumab plus methotrexate	SURPRISE Study Group	marketed	IL-6 receptor antagonist + DMARD combination	IL-6 receptor (tocilizumab); dihydrofolate reductase (methotrexate)
Recaticimab and Statin	Recaticimab and Statin	Peking Union Medical College Hospital	marketed	IL-6 inhibitor monoclonal antibody + HMG-CoA reductase inhibitor	IL-6 receptor / HMG-CoA reductase
TCI507	TCI507	National Taiwan University Hospital	marketed	IL-6 inhibitor monoclonal antibody	IL-6 or IL-6 receptor
Placebo to tocilizumab	Placebo to tocilizumab	Hoffmann-La Roche	marketed	IL-6 receptor antagonist	IL-6 receptor (IL-6R)
Tocilizumab(400mg)	Tocilizumab(400mg)	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	marketed	IL-6 receptor antagonist (monoclonal antibody)	IL-6 receptor (IL-6R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-inflammatory class)

A. Vogel AG · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Marie Hudson, MD · 1 drug in this class
Organon and Co · 1 drug in this class
Panacea Biotec Ltd · 1 drug in this class
Prof. Dr. Stephan Weidinger · 1 drug in this class
Salus Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-IL6 — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-il6. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab